LENZ Therapeutics, Inc. (LENZ) Form 10-Q — Nov 3, 2026
LENZ Therapeutics' Q3 2026 net loss more than doubled to $31.0 million from $16.7 million a year ago, with nine-month losses of $104.4 million as SG&A surged 133% to $120.2 million on its direct-to-consumer VIZZ launch campaign featuring Sarah Jessica Parker. Product sales remain early-stage at $2.6 million in Q3 (~38,000 packs) and $6.0 million for the nine months, far below the commercial spend ramp, and VIZZ is the company's only product with no pipeline candidates behind it.
Key figures
- Revenue
- 3384000
- Total Debt
- 0
- Revenue Yoy
- Total revenue $3.4M in Q3 2026 vs $12.5M in Q3 2025
- Total Assets
- 209749000
- Cash Position
- $30.6M cash and equivalents; $197.3M including marketable securities
- Shares Outstanding
- 31420583
- Q3 sga
- $35.8M, +30% YoY
- Nine month sga
- $120.2M, +133% YoY
- Q3 product sales
- $2.6M (~38,000 packs)
- Accumulated deficit
- $331.5M
- Headcount reduction
- ~75% to ~40 full-time employees
- Nine month net loss
- $104.4M vs $46.2M prior year
- Advertising spend 9m
- $36.3 million
- Restructuring charges
- ~$5 million
- Operating cash burn 9m
- $94.6M
- Nine month product sales
- $6.0M (~90,000 packs)
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.